"10.1371_journal.pone.0093745","plos one","2014-04-03T00:00:00Z","Marc Cartellieri; Stefanie Koristka; Claudia Arndt; Anja Feldmann; Slava Stamova; Malte von Bonin; Katrin Töpfer; Thomas Krüger; Mathias Geib; Irene Michalk; Achim Temme; Martin Bornhäuser; Dirk Lindemann; Gerhard Ehninger; Michael P Bachmann","Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Helmholtz Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radioimmunology, Dresden, Germany; Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Neurosurgery, Section Experimental Neurosurgery and Tumor Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Institute of Virology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany","Conceived and designed the experiments: MC MPB. Performed the experiments: MC CA SK MG TK IM KT MvB MB AT. Analyzed the data: MC MvB KT. Contributed reagents/materials/analysis tools: AF SS CA DL MB AT GE. Wrote the paper: MC SK MPB.","Michael P. Bachmann is a PLOS ONE Editorial Board member. This does not alter the authors adherence to PLOS ONE Editorial policies and criteria. SS, GE, and MB hold patents related to anti-PSCA, anti-La and anti-CD33 antibodies (DE 10 2011 118 022.6 Antikörper gegen das Prostata-spezifische Stammzellantigen und dessen Verwendung, DE 10 2010 039 018.6 Anti-La Antikörper und ihre Anwendung zum Immunotargeting, DE 10 2009 045 006.8 Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen). This does not alter the authors adherence to all PLOS ONE policies on sharing data and materials.","2014","04","Marc Cartellieri","MC",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
